STSA-1002 not checked
Staidson (Beijing) Biopharmaceuticals Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome”In the company’s words, NCT07208591 on ClinicalTrials.gov
Other drugs for Acute Respiratory Distress Syndrome (ARDS)
- APC-0101Aerogen Pharma Limited · Phase 3
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- SecretomePT. Prodia Stem Cell Indonesia · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2026 | To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | |
| Phase 1/2Completed | 20 Mar 2025 | To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome | |
| Phase 1Completed | 31 Mar 2022 | The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects | |
| Phase 1Completed | 12 Jan 2023 | The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects | |
| Phase 1Completed | 6 Apr 2023 | A Study of STSA-1002 in Healthy Subjects | |
| Phase 1Completed | 11 Apr 2023 | The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects | |
| Phase 1Terminated | 26 Mar 2024 | A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026